Fri, August 6, 2021

Keay Nakae Maintained (ARWR) at Strong Buy with Decreased Target to $94 on, Aug 6th, 2021

Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Decreased Target from $97 to $94 on, Aug 6th, 2021.

Keay, nor any peers, have made any analyst calls on ARWR in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30